Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Veritone Inc (VERI) Price & Performance

Davita IncTrade
Veritone IncTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Veritone Inc — how do they compare? Davita Inc trades at $179.56 (market cap $11.29B), while Veritone Inc trades at $0.59 (market cap $59.46M). The key difference: Davita Inc is far larger — about 189.9× Veritone Inc's market cap, and Davita Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Veritone Inc for 12 Days on average.

DVAVERI
Market Cap
$11.29B$59.46M
Volume
582,20415,523,164
Sector
HealthTechnology
52-Week High
$240.96$8.39
52-Week Low
$103.87$0.59
Typical Hold Time
113 Days12 Days
Enterprise Value
$24.01B$94.86M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.

DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.

Veritone Inc

Veritone (VERI) trades at $0.61, down 11.76% in the last 24 hours, reflecting bearish technical signals. The company reported a net loss of $111.73 million in 2025, with negative profit margins and cash flow challenges, though revenue remains near $92 million. Recent news includes a $15 million equity offering and partnerships, but legal investigations and persistent losses weigh on sentiment.

The outlook is highly speculative, with a consensus price target of $3.75 suggesting significant upside if the company achieves profitability. However, high execution risk, cash burn, and legal overhangs present substantial downside, making the stock suitable only for risk-tolerant investors betting on a turnaround.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
91% Buy9% Sell
Avg holding period · 113 Days
VERI
7% Buy93% Sell
Avg holding period · 12 Days

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About Veritone Inc

Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.

Read more on VERI →